Nilutamide
SIGMA/N8534 - solid
Synonym: 5,5-
CAS Number: 63612-50-0
Empirical Formula (Hill Notation): C12H10F3N3O4
Molecular Weight: 317.22
MDL Number: MFCD00864670
Linear Formula: C12H10F3N3O4
Product Type: Chemical
| form | solid |
| InChI | 1S/C12H10F3N3O4/c1-11(2)9 |
| InChI key | XWXYUMMDTVBTOU-UHFFFAOYSA |
| originator | Sanofi Aventis |
| Quality Level | 200 ![]() |
| SMILES string | CC1(C)NC(=O)N(c2ccc(c(c2) |
| Application: | Nilutamide has been used: • as a nuclear androgen receptor (nAR) inhibitor to study its effects on oocyte maturation in zebrafish • to determine its effects on bioluminescent Saccharomyces cerevisiae bioreporters in BLYAS assay • as a substrate in hydrogenation reaction |
| Biochem/physiol Actions: | Nilutamide is a nuclear androgen receptor inhibitor. It is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone to the androgen receptor. Nilutamide shows a therapeutic effect against prostate cancer. |
| Features and Benefits: | This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Sanofi Aventis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 1 g in glass bottle |
| Symbol | ![]() GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H301 - H360 |
| Precautionary statements | P201 - P301 + P310 + P330 |
| Hazard Codes | T |
| Risk Statements | 60-25 |
| Safety Statements | 36/37/39-45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| UNSPSC | 51111800 |



